- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03841058
Phase II Trial of Abaloparatide vs. Placebo in Post-Menopausal Women Receiving Initial Spinal Fusion Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective randomized, double-blinded, placebo-controlled, phase 2, 12-month pilot to study the efficacy of abaloparatide in postmenopausal women needing lumbar spinal fusion surgery. Seventy-two women with low bone mass who are scheduled to undergo spinal fusion surgery will be randomized 2:1 in a blinded fashion to receive either 80 mcg of abaloparatide subcutaneously (SC) every day or an identical-appearing placebo SC for 6 months. This study has 3 objectives:
- In this pilot study we will evaluate surgical outcomes at one year and the primary outcome will be fusion based on CT exam with categories of Fusion/ Indeterminate/ Not fused and this will be compared between groups receiving 6 months of abaloparatide vs. placebo. Secondary outcomes for surgical success will be evidence of pedicle screw loosening, adjacent segment fracture and proximal junctional kyphosis. This data will be used to determine effect sizes and variance to power the next larger clinical trial.
- To determine if abaloparatide/Tymlos versus placebo leads to a faster reduction in pain as assessed by both the Numeric Rating Scale (NRS) and the Oswestry Disability Index (ODI) for low back pain at 6 months.
- As an exploratory proof of concept objective we will determine if abaloparatide/Tymlos versus placebo results in greater fusion bone mass volume (FBMV) as a marker of bone union at 6 months and 1 year to see whether at one year post lumbar spinal fusion surgery, greater FBMV is associated with improved spinal surgery outcomes including: enhanced bone union, reduced pedicle screw loosening, adjacent segment fracture and proximal junctional kyphosis. This would serve as evidence that FBMV can be used as an early validated marker of fusion surgery success.
All analyses will be two-sided and the alpha level will be set at 0.05. FBMV, pain and function will be compared by drug (Abaloparatide vs. placebo) at 6 months. Compliance will be considered as taking 80% of the study drug. For the primary analysis we will evaluate bone union and reduced pedicle screw loosening, adjacent segment fracture, and proximal junctional kyphosis as dichotomous variables at 12 months using logistic regression and comparing the placebo group to the abaloparatide group. We will also evaluate FBMV as a continuous variable and evaluate differences in this outcome between abaloparatide and placebo groups at 6 months as an exploratory outcome variable. We will determine if FBMV differs in those with or without markers of surgical success for validity of FBMV, regardless of prior treatment group. In addition, these data will be used to determine effect sizes and variance to power the next larger clinical trial.
We will evaluate NRS and ODI score by using repeated measures of these variables over time by treatment group and evaluate NRS at 6 months in the placebo versus abaloparatide group. Comorbidity, age, prior fracture, prior use of bisphosphonates and other covariates will be evaluated, via multivariable regression, as to whether they lead to a change in the estimate of effect in order to be considered for inclusion in the models.
If abaloparatide can improve outcomes following lumbar spine fusion surgery, this pilot study could lead to the requisite two year trial that may have an impact on the treatment of fusion surgery patients.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Joseph Raphael
- Phone Number: (646) 797-8797
- Email: raphaelj@hss.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Recruiting
- Hospital For Special Surgery
-
Contact:
- Joseph Raphael
- Phone Number: 646-797-8797
- Email: raphaelj@hss.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Postmenopausal women (defined as >12 months since last menstrual cycle)
- Age of 50 years or older,
- Requiring posterolateral lumbar spine fusion surgery (L1-2; L2-3; L3-4; L4-5, L5-S1) with single or multi-level fusion for degenerative conditions of the lumbar spine (including lumbar degenerative disk disease, severe instability, high grade spondylolisthesis, deformity, degenerative scoliosis, pseudoarthrosis, and spinal stenosis) under the care of spine surgeons at the Hospital for Special Surgery.
Exclusion Criteria:
- Hypersensitivity to abaloparatide
- Patients with increased risk of osteosarcoma: Paget's disease, prior radiation therapy
- Patients with active hypercalcemia or current diagnosis of hyperparathyroidism
- History of multiple renal calculi or renal calculus within 2 years
- Unexplained elevations in alkaline phosphatase
- Evidence of metastatic cancer or multiple myeloma.
- Patients unwilling to take placebo or abaloparatide.
- Patients whose surgery is for a revision to a prior lumbar spinal fusion surgery
- Chronic oral steroids (>= 7.5 mg prednisone/d currently and for more than 1 month) for an inflammatory comorbid diagnosis
- Patients who cannot understand and sign the informed consent
- Patients who are unable to meet the proposed follow-up schedule
- Patients with >1 year of prior cumulative treatment with Forteo and/or Tymlos, or any use of Forteo or Tymlos within the 6 months prior to enrollment.
- Patients who have received bisphosphonate treatment of >1 year in past 5 years
- Patients who are current smokers
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Abaloparatide
Abaloparatide 80 mcg dose administered subcutaneously with a pen once daily for 6 months
|
80 mcg delivered SC by a pen
Other Names:
|
Placebo Comparator: Placebo
Placebo administered subcutaneously with a pen once daily for 6 months
|
A pen to deliver a SC dose of placebo
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in measure of fusion mass bridging from transverse process to transverse process
Time Frame: one year
|
CT assessment of fusion mass using a qualitative five-point scale to assess fusion quality (1 = unfused, 2 = partial unilateral fusion, 3 = partial bilateral fusion, 4 = complete unilateral fusion, 5 = complete bilateral fusion)
|
one year
|
Difference in incidence of adverse surgical outcomes
Time Frame: one year
|
Adverse outcomes include pedicle screw loosening, adjacent segment fracture and proximal junctional kyphosis will be evaluated on CT images
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain assessed by the Numeric Rating Scale
Time Frame: 6 months
|
Numeric Rating Scale (NRS) from 0 to 10 with higher scores indicating more pain.
|
6 months
|
Pain assessed by the Oswestry Disability Index
Time Frame: 6 months
|
Oswestry Disability Index for low back pain with a score of 0 to 50 points or 0 to 100%.
Higher scores indicate more pain.
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CT evaluation of Fusion bone mass volume
Time Frame: 6 months and 1 year
|
fusion bone mass volume (FBMV) as a marker of bone union will be assessed on CT images
|
6 months and 1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Emily Stein, MD, Hospital for Special Surgery, New York
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-0287 (Other Identifier: M D Anderson Cancer Center)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Fusion
-
National Taiwan University HospitalTerminatedLumbar Fusion | Lumbar Spinal Fusion SurgeryTaiwan
-
Xtant MedicalRTI SurgicalRecruitingJoint Diseases | Musculoskeletal Diseases | Spinal Stenosis | Fusion of Spine | Spine | Spinal Fusion | Spinal Disease | Spinal Instability | Sacroiliac; Fusion | Fusion of Joint | SacroiliacUnited States, Spain, Germany
-
Sewon Cellontech Co., Ltd.UnknownSpinal Fusion Acquired | Fusion of Spine (Disease)Korea, Republic of
-
AO Foundation, AO SpineNot yet recruiting
-
M.C. Kruyt, MD, PhDKuros BioSciences B.V.Active, not recruitingSpinal FusionNetherlands
-
Montefiore Medical CenterTerminated
-
Taipei Veterans General Hospital, TaiwanCompleted
-
Assiut UniversityUnknown
-
Children's Hospital of PhiladelphiaChildren's Anesthesiology Associates, Ltd.Completed
-
Istituto Ortopedico RizzoliRecruiting
Clinical Trials on Abaloparatide
-
Radius Health, Inc.Medpace, Inc.Completed
-
Radius Health, Inc.CompletedPostmenopausal OsteoporosisUnited States, Poland, Denmark, Hungary, Puerto Rico
-
Radius Health, Inc.Nordic Bioscience A/SCompletedPost Menopausal OsteoporosisPoland, Denmark, United States, Estonia
-
Radius Health, Inc.Medpace, Inc.CompletedOsteoporosisUnited States
-
Radius Health, Inc.Completed
-
Radius Health, Inc.CompletedOsteoporosis | Postmenopausal OsteoporosisHong Kong, United States, Poland, Romania, Estonia, Czech Republic, Argentina, Brazil, Denmark, Lithuania
-
Hospital for Special Surgery, New YorkNew York University; Icahn School of Medicine at Mount Sinai; Weill Medical College... and other collaboratorsActive, not recruiting
-
Radius Health, Inc.CompletedOsteoporosis | Age Related Osteoporosis | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of VertebraeUnited States, Poland, Italy
-
University of RochesterCompletedMyelodysplastic Syndromes | Chronic Myelomonocytic LeukemiaUnited States
-
University of Wisconsin, MadisonRadius Health, Inc.Active, not recruitingOsteoporosis | Arthroplasties, Knee ReplacementUnited States